Skip to main content

Briacell Therapeutics Corp(BCT-T)
TSX

Today's Change
Real-Time Last Update
Day Low6.81
Day High6.81
Open:6.81
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Wednesday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp up on Monday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Friday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Thursday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Wednesday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Tuesday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Monday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Friday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp up on Thursday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Wednesday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp flat on Tuesday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp up on Monday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Friday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Thursday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp up on Wednesday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Tuesday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Friday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Friday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp up on Thursday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Wednesday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Tuesday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Monday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp up on Friday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp up on Thursday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp up on Wednesday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp up on Tuesday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp flat on Monday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Friday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Thursday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp up on Wednesday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Tuesday (BCT)
AI-generated - The Globe and Mail
Closing Bell: Briacell Therapeutics Corp down on Monday (BCT)

Profile

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.